Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketotifen is an antihistamine and mast cell stabilizer used to treat allergic conditions such as conjunctivitis (allergic pinkeye), asthma, urticaria (hives), atopic dermatitis (eczema), and systemic mast cell diseases like mastocytosis and mast cell activation syndrome. Available in both oral and ophthalmic forms, it reduces the frequency and severity of asthma symptoms when taken daily with other antiasthmatic medications but is not effective for acute attacks. Ketotifen acts primarily as a non-competitive antagonist of the histamine H1 receptor—blocking histamine-mediated reactions such as itching and swelling—and stabilizes mast cells to inhibit the release of inflammatory mediators including histamine, leukotrienes, prostaglandins, tryptase, and platelet-activating factor. Additional mechanisms include leukotriene antagonism and phosphodiesterase inhibition. Its effects may take 6–12 weeks to become apparent[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketotifen.